Risankizumab
Based on 1 Customer Validation
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.37%
- No. CAS: 1612838-76-2
- Peso molecular:145.92 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Human IgG1 (L234A/L235A) kappa
Human
|
IL-23 <10 pM (Kd) |
Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with Kds <10 pM[3].
Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days)[3]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dosage
-
Result:Significantly inhibited IL23-induced ear swelling and cytokine production.
-
Animal Model:Cynomolgus monkeys[3]
-
Dosage:1.0 mg/kg
-
Administration:i.v. or s.c.
-
Result:Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys[1].
IV (1 mg/kg) SC (1 mg/kg) AUCinf (μg·day/mL) 202 ± 33.5 142 ± 33.3 CL (mL/day/kg) 5.18 ± 0.8 / Vd, ss (mL/kg) 88.3 ± 3.12 / t1/2 (h) 12.2 ± 2.28/ 9.15 ± 1.87 Cmax (μg/mL) / 10.1 ± 3.14 Tmax (day) / 2.11 ± 1.84 F (%) / 70.4 ± 16.5
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling IL-23A (red) with Risankizumab (anti-IL-23A) (HY-P99248). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
No. CAS 1612838-76-2
-
Appearance Liquid
-
Peso molecular 145.92 kDa
-
Color Colorless to light yellow
-
SMILES
[Risankizumab]
-
Synonyms
Risankizumab rzaa; BI 655066; ABBV-066
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)